Featured Article

Living with chronic migraines can be an incredibly debilitating and frustrating experience. Those who suffer from this condition know all too well the crippling pain, sensitivity to light and sound, and the disrupted daily life that come with each migraine attack. Fortunately, a new treatment option has emerged, offering hope to chronic migraine sufferers - emgality. And with the availability of a free trial for this medication, its positive benefits can be experienced by many.

Emgality is a monthly injectable medication that works by blocking the activity of a protein called calcitonin gene-related peptide (CGRP), which is thought to play a role in the development of migraines. This groundbreaking treatment was approved by the US Food and Drug Administration (FDA) in 2018, making it the first-ever drug specifically designed for the prevention of chronic migraines.

Since its approval, emgality has shown to be highly effective in reducing the frequency and severity of migraines. In clinical trials, it has been shown to reduce the number of monthly migraine days by 50% or more for most patients. This means fewer migraine attacks, less time spent in pain, and more time to focus on living life to the fullest.

The benefits of emgality are not limited to just headache relief. Many chronic migraine sufferers also experience other debilitating symptoms such as nausea, vomiting, and dizziness during an attack. Emgality has been shown to reduce these symptoms as well, allowing patients to feel more in control of their day-to-day lives.

One of the greatest advantages of emgality is that it is a preventive treatment, meaning it can help reduce the occurrence of migraines rather than just treating the symptoms after they have already started. This is significant because many sufferers rely on pain relief medications, which can come with a host of side effects and may not even be effective in preventing migraines.

Perhaps one of the most appealing aspects of the emgality free trial is that it allows patients to try the treatment before committing to it long-term. This is especially beneficial for those who may be hesitant to start a new medication or have tried multiple treatments in the past with little success. With the free trial, patients can experience the positive effects of emgality without the financial burden.

In addition to its effectiveness, emgality is also easy to use. It comes in the form of a prefilled pen that can be self-administered at home, making it convenient for patients to incorporate into their routine. As a preventive treatment, emgality is taken once a month, making it a manageable option for those with busy schedules.

There is also promising news for those who may not have access to healthcare coverage. The makers of emgality, Eli Lilly and Company, offer a patient assistance program to help lower the cost of the medication for those who qualify. This program is another demonstration of the commitment to making emgality accessible to those who need it most.

Overall, the availability of the emgality free trial brings a wealth of positive benefits to the chronic migraine community. From its effectiveness in reducing the frequency and severity of attacks to its convenience and accessibility, this new treatment offers a ray of hope for those living with this debilitating condition. If you are a chronic migraine sufferer, consider giving emgality a try - the positive benefits may change your life.